AHS
PPH icon

Aspiriant Holdings S3’s VanEck Pharmaceutical ETF PPH Stock Holding History

Aspiriant Holdings S3’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$3.94M Sell
60,272
-1,100
-2% -$71K 1.69% 20
2015
Q3 		$3.87M Buy
61,372
+935
+2% +$65.7K 1.78% 18
2015
Q2 		$4.28M Sell
60,437
-273
-0.4% -$19.7K 1.71% 16
2015
Q1 		$4.26M Sell
60,710
-55
-0.1% -$3.73K 1.7% 23
2014
Q4 		$3.9M Buy
+60,765
New +$3.87M 1.61% 21

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
SCM
Stuyvesant Capital Management Armonk, New York $41.1M AUM 17.11% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
SB
Suntrust Banks Atlanta, Georgia $19.2B AUM 0.83% 1-Year Est. Return

Aspiriant Holdings S3's PPH Position: Q4 2015 in Review

Aspiriant Holdings S3 reduced its VanEck Pharmaceutical ETF (PPH) stake by 1.8% in Q4 2015, selling an estimated $71K and leaving 60,272 shares worth $3.94M. The position accounts for 1.69% of the portfolio, ranked #20.

Aspiriant Holdings S3 first reported a position in PPH in Q4 2014 and has held it in 5 quarters since. The position peaked at $4.28M in Q2 2015. 59 funds tracked by Wall St. Rank hold PPH as of Q4 2015.

  • Aspiriant Holdings S3 held 60,272 shares of VanEck Pharmaceutical ETF worth $3.94M as of Q4 2015.
  • Aspiriant Holdings S3 sold 1,100 VanEck Pharmaceutical ETF shares in Q4 2015, an estimated $71K.
  • VanEck Pharmaceutical ETF made up 1.69% of Aspiriant Holdings S3's portfolio in Q4 2015, its #20 holding.
  • Aspiriant Holdings S3 first reported a position in VanEck Pharmaceutical ETF in Q4 2014 and has held it in 5 quarters since.
  • Aspiriant Holdings S3's VanEck Pharmaceutical ETF position peaked at $4.28M in Q2 2015.
  • 59 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2015.

Based on Aspiriant Holdings S3's 13F filing for Q4 2015, filed 13 Jan 2016.